专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0136602A3 PAK5 A MEMBER OF THE P21-ACTIVATED KINASE (PAK) PROTEIN FAMILY, NUCLEIC ACIDS AND METHODS RELATED TO THE SAME 审中-公开
标题翻译： PAK5 P21激活的激酶（PAK）蛋白家族成员，核酸及其相关方法
公开(公告)号：WO0136602A3
公开(公告)日：2001-10-04
申请号：PCT/EP0010736
申请日：2000-11-14
申请人： PHARMACIA & UPJOHN SPA , DAHLBERG MATS , MOLL JURGEN , GALVANI ARTURO
发明人： DAHLBERG MATS , MOLL JURGEN , GALVANI ARTURO
IPC分类号： G01N33/50 , A61K38/46 , A61K39/00 , A61K39/395 , A61K48/00 , A61P9/00 , A61P25/00 , A61P35/00 , A61P37/06 , C07K16/40 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/10 , C12N9/12 , C12N15/09 , C12P21/08 , C12Q1/48 , C12Q1/68 , G01N33/15 , G01N33/53 , A61K38/45 , A61K121/00 , C12N1/14 , C12N1/20 , C12N15/54 , C12N15/63
CPC分类号： C12N9/1205 , A61K39/00 , C12Y207/01037
摘要： The present invention provides a human polypeptide homolog of P21-activated kinase (PAK) polynucleotides which identify and encode PAK5 serine/threonine kinase. In addition, the inventon provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of PAK5 agonists/antagonists, useful for the treatment of human diseases and conditions.
摘要翻译：本发明提供鉴定和编码PAK5丝氨酸/苏氨酸激酶的P21活化激酶（PAK）多核苷酸的人多肽同源物。此外，本发明提供表达载体，宿主细胞及其生产方法。本发明还提供了用于鉴定可用于治疗人类疾病和病症的PAK5激动剂/拮抗剂的方法。

2. 发明申请

WO2005059119A3 DIFFERENTIATED CELLS 审中-公开
标题翻译：分化细胞
公开(公告)号：WO2005059119A3
公开(公告)日：2005-08-11
申请号：PCT/GB2004005232
申请日：2004-12-14
申请人： UNIV DURHAM , JAHODA COLIN ALBERT BUCHANAN , REYNOLDS AMANDA JANE , WHITEHOUSE CLAIRE JENNA , HOLE NICHOLAS
发明人： JAHODA COLIN ALBERT BUCHANAN , REYNOLDS AMANDA JANE , WHITEHOUSE CLAIRE JENNA , HOLE NICHOLAS
IPC分类号： A61K35/12 , C12N5/071 , C12N5/077 , C12N5/06 , A61K121/00
CPC分类号： C12N5/0666 , A61K35/12 , C12N5/0627
摘要： The adult hair follicle dermal papilla and dermal sheath cell are developmentally active cell populations with a proven role in adult hair follicle cycling activity and unique inductive powers. In stein cell biology, the hair follicle epithelium has recently been the subject of a great deal of investigation, but up to now the follicle dermis has been largely overlooked as a source of stein cells. Following the sporadic appearance of muscle, lipid and bone-type cells in discretely isolated follicle dermal papilla and sheath cell primary cultures, we demonstrated that cultured papilla and sheath cell lines were capable of being directed to lipid and bone differentiation. Subsequently, for the First time, we produced clonal dermal papilla and sheath lines that had extended proliferative capabilities. Dye exclusion has been reported to be an identifying feature of stein cells, therefore clonal papilla and sheath lines with differing capacity to exclude rhodamine (123) were cultured in medium known to induce adipocyte and osteocyte differentiation. Both dermal sheath and dermal papilla-derived clones showed the capacity to make lipid and to produce calcified material, however different clones had varied behaviour and there was no obvious correlation between their stein cell capabilities, and dye exclusion or selected gene expression markers. As a highly accessible source, capable of being discretely isolated, the follicle has important potential as a stein cell source for tissue engineering and cell therapy purposes. It will also be interesting to compare follicle dermal stein cell properties with the broader stein cell capabilities discovered in skin dermis, and investigate whether the follicle is a key dermal stein cell niche. Finally, the discovery of stein cells in the dermis may have implications for certain pathologies in which abnormal differentiation occurs in the skin.
摘要翻译：成人毛囊真皮乳头和真皮鞘细胞是具有发育活性的细胞群，其在成人毛囊周期活动和独特的感应能力中具有证实的作用。在stein细胞生物学中，毛囊上皮细胞最近已经成为大量研究的主题，但到目前为止，卵泡真皮已被广泛忽视作为stein细胞的来源。继散在分离的毛囊真皮乳头和鞘细胞原代培养物中的肌肉，脂质和骨型细胞出现后，我们证明培养的乳头和鞘细胞系能够导向脂质和骨分化。随后，第一次，我们产生了具有延长的增殖能力的克隆真皮乳头和鞘线。已报道染料排斥是斯坦细胞的识别特征，因此具有不同排斥罗丹明（123）能力的克隆乳头和鞘线在已知诱导脂肪细胞和骨细胞分化的培养基中培养。真皮鞘和真皮乳头衍生的克隆都表现出产生脂质和产生钙化物质的能力，然而不同克隆具有不同的行为，并且它们的斯氏细胞能力，染料排除或选择的基因表达标记之间没有明显相关性。作为高度可获得的来源，能够被分离分离，卵泡具有作为组织工程和细胞治疗目的的斯坦细胞来源的重要潜力。将皮肤毛囊真皮细胞特性与皮肤真皮中发现的更广泛的皮肤细胞能力相比较，并研究毛囊是否是关键皮肤硬脂细胞生态位也是有意义的。最后，真皮中的斯氏细胞的发现可能对皮肤中发生异常分化的某些病理有影响。

3. 发明申请

WO0074723A3 METHODS FOR THE GENE THERAPY OF BENIGN PROSTATIC HYPERPLASIA AND MEDICAL AGENTS THEREFORE 审中-公开
标题翻译： BENIGN PROSTATIC HYPERPLASIA及其药物代谢基因治疗方法
公开(公告)号：WO0074723A3
公开(公告)日：2001-04-12
申请号：PCT/EP0003448
申请日：2000-04-17
申请人： JENAPHARM GMBH , CHEON JUN , KIM JE JONG , MOON DU GEON
发明人： CHEON JUN , KIM JE JONG , MOON DU GEON
IPC分类号： A61K38/17 , A61K48/00 , C12N15/861 , C12N15/85 , A61K121/00
CPC分类号： C12N15/86 , A61K38/1709 , A61K48/00 , C12N2710/10343 , C12N2710/10345 , C12N2830/008
摘要： Disclosed are 1) gene medical agents (Gene Therapeutic Drugs) for the treatment of benign prostatic hyperplasia (BPH) and 2) treatment methods using them such as TUMAP (TransUrethral Molecular Ablation of Prostate) and TRMAP(TransRectal Molecular Ablation of Prostate) . The gene medical agents comprise structural genes able to cause the apoptosis of BPH cells, in combination with regulator genes able to guide the expression of the structural genes targetting specifically on BPH tissues, in carriers. When being administered to lesion foci of BPH tissues, the gene medical agents allow the selective elimination of BPH cells and also prostatic cancer cells developed concurrently that could be the another important merit of this invention. In treating, the carriers are administered directly to the tumor cells of BPH via a transurethral route (TUMAP) or a transrectal route (TRMAP) . This novel, non-invasive method allows BPH tissues to be selectively removed with ease without any side effects such as pain, hemorrhage, etc.
摘要翻译：公开的是1）用于治疗良性前列腺增生（BPH）的基因医药（Gene Therapeutic Drugs））和2）使用它们的治疗方法，例如TUMAP（前列腺的TransUrethral分子消融）和< TRMAP（前列腺的TransRectal分子消融）。基因药物包含能够引起BPH细胞凋亡的结构基因，与能够指导特异性靶向BPH组织的结构基因在载体中的表达的调节基因组合。当被施用于BPH组织的病变灶时，基因医学试剂允许选择性消除BPH细胞，并且同时发展的前列腺癌细胞可能是本发明的另一重要优点。在治疗中，载体通过经尿道途径（TUMAP）或经直肠途径（TRMAP）直接施用于BPH的肿瘤细胞。这种新颖的非侵入性方法允许BPH组织被轻易地选择性地去除而没有任何副作用，例如疼痛，出血等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式